Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Regeneron Pharmaceuticals (NQ: REGN)
544.01 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 4:11 AM EDT, May 28, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 109
Open 544.01
Bid (Size) 540.00 (2)
Ask (Size) 553.87 (1)
Prev. Close 544.01
Today's Range 544.01 - 544.01
52wk Range 271.37 - 583.54
Shares Outstanding 105,949,824
Dividend Yield N/A
Performance
YTD
+45.71%
+45.71%
1 Month
-0.64%
-0.64%
3 Month
+18.80%
+18.80%
6 Month
+46.40%
+46.40%
1 Year
+76.67%
+76.67%
Top News
More News
Regeneron Announces Pricing of Secondary Offering of its Common Stock Held by Sanofi
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the pricing of the underwritten public secondary offering of 11,831,496 shares of its common stock held by Sanofi at a price of $515.00... Read More
from PR Newswire
Sanofi announces pricing of Regeneron stock offering
from GlobeNewswire News Releases
More News
Read More
Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
from GlobeNewswire News Releases
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
from PR Newswire
REFILE-BRIEF-FDA Approves Regeneron's Dupixent For Children Aged 6-11 Yrs With Moderate-To-Severe Atopic Dermatitis
category companyNews
from Reuters: Company News
Deals of the day-Mergers and acquisitions
category companyNews
from Reuters: Company News
Dow Jones Futures: Vertex, Netflix, Microsoft, Google, Tesla, ServiceNow, Regeneron, Workday Rebound Bullishly In Coronavirus Market Rally; Boeing 737 Max Production Resumes
from Investor's Business Daily
UPDATE 2-Rising Swiss rivalry as Roche and Novartis target same diseases
category companyNews
from Reuters: Company News
Dow Jones Gains 890 Points In 2 Days, Small Caps Surge; Sell These Growth Stocks Or Buy?
from Investor's Business Daily
UPDATE 1-Roche, Novartis highlight intensifying rivalry in eye disease, MS
category companyNews
from Reuters: Company News
Notable Tuesday Option Activity: NVDA, AZO, REGN
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.